Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

More documents

Recommendations

Info

Arbiter 3: Changes in CIMT in Patients Treated With Statins or Statins + Niacin Average Change in CIMT For All Drug Periods (mm) - - - .075 .050 .025 0 .025 .050 .075 N = 61 Statin Progression Regression N = 125 Statin + Niacin 12 Months Treatment Period Taylor A. et al Curr. Med. Res. Opin. 2006:22,2243-2250 N = 67 24 Months
� � Aim High randomized 3414 patients with established CVD– 85% men � 34% Diabetic and 81% Metabolic Syndrome � Patients will receive simvastatin +/- Ezetimibe to target <strong>LDL</strong>-C to 40-80 or simvastatin +/- Ezetimibe + niacin Baseline lipids: <strong>LDL</strong>- C = 71 mg/dl, HDL-C = 34.9 mg/dl, Tg = 161 mg/dl. � Trial Terminated May 2011 AIM HIG Investigators. Am Heart J. 2011;161(3):538-543. 35
Page 1 and 2: Treating Lipid Abnormalities Beyond
Page 3 and 4: THE PYRAMID OF CVD TRIALS Very high
Page 5 and 6: UNMET CLINICAL NEED TREATMENT OF TH
Page 7 and 8: Lipoprotein Metabolism in Patients
Page 9 and 10: LOW HDL-C AS A RESIDUAL RISK FACTOR
Page 11 and 12: THE BEGINNING …
Page 13 and 14: THE RESULT… OF THE SUPER SIZED LI
Page 15 and 16: Current Insights into the Mechanism
Page 17 and 18: Lipid Poor ApoA-I and αHDL αHDL i
Page 19 and 20: Intestine ApoA-I Current Model of H
Page 21 and 22: COLLAR-INDUCED CHANGES IN ENDOTHELI
Page 27 and 28: Potential Mechanisms Involved in th
Page 29 and 30: Increasing HDL By Infusion of HDL,
Page 31 and 32: HDL Targeted Therapies: Niacin 1. D
Page 33: HATS: Angiographic and Clinical End
Page 37 and 38: Change in IVUS Total Atheroma Volum
Page 39 and 40: Future HDL Targeted Therapies 1. Pr
Page 41 and 42: Preβ-HDL Infusion Reduced Arterial
Page 43 and 44: Preβ-HDL Enriched Plasma Obtained
Page 45 and 46: The Reduction in Plaque was Greater
Page 47 and 48: Intestine ApoA-I Lipoprotein Profil
Page 49 and 50: 10 mg 30 mg 60 mg Plasma HDLC and L
Page 51 and 52: ILLUMINATE: Investigation of Lipid
Page 53 and 54: CETP Inhibitors CETP Torcetrapib Da
Page 55 and 56: The dal-HEART Program: Dalcetrapib
Page 57 and 58: LDL (mg/dL) Define Trial: Effect of
Page 59: FUTURE THERAPY FOR CARDIOVASCULAR D

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

Create successful ePaper yourself

Delete template?

Save as template?